STOCK TITAN

Nexalin Technology, Inc. - NXL STOCK NEWS

Welcome to our dedicated page for Nexalin Technology news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Technology stock.

Nexalin Technology, Inc. (NASDAQ: NXL) is a pioneering company in the field of neurostimulation, offering non-invasive and drug-free therapies for individuals suffering from anxiety, depression, and insomnia. The company has developed a patented device that uses transcranial electrical stimulation (tES), producing a unique waveform designed to stimulate brain activity and normalize neurochemical levels. This treatment aims to provide lasting relief from mental health conditions without the adverse side effects typically associated with drugs or psychotherapy.

One of the core products from Nexalin is the Gen-1 device, classified as a Class II medical device by the U.S. Food and Drug Administration (FDA). This cranial electrotherapy stimulation (CES) device emits a waveform at 4 milliamps during treatments and has been shown to increase beta-endorphins significantly during clinical trials.

Nexalin is also advancing the development of its Gen-2 and Gen-3 HALO™ Clarity devices, which aim to offer deeper brain penetration and enhanced patient response without side effects. The company's Gen-2 device was recently approved by the National Medical Products Administration (NMPA) in China for treating insomnia and depression and is distributed in the Asia Pacific region through a joint venture with Wider Come Limited.

Recent achievements include a collaborative study involving the U.S. Department of Veterans Affairs and UC San Diego, which demonstrated a significant decrease in post-concussion syndrome (PCS) and PTSD symptoms in veteran patients using the Gen-2 device. Moreover, the company continues to gather clinical data supporting its neurostimulation technology and is making progress in advancing its new Gen-3 HALO™ Clarity Virtual Clinic model.

Nexalin is committed to addressing the global mental health crisis through innovative solutions. The company's non-invasive devices are developed to be undetectable to the human body, ensuring a comfortable treatment experience. With ongoing research and development, Nexalin aims to extend the reach of its therapies to benefit more people worldwide.

Rhea-AI Summary

Nexalin Technology closed a public offering of 3,000,000 shares of common stock at $1.75 per share, raising approximately $5.25 million in gross proceeds before fees and expenses. The offering was facilitated by Maxim Group as the sole placement agent.

The shares were registered under a Form S-1 registration statement, which the SEC declared effective on June 27, 2024. A final prospectus was filed on June 28, 2024, and the offering concluded on July 1, 2024.

This announcement does not constitute an offer or solicitation to sell these securities in any jurisdiction where such would be unlawful.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
-
Rhea-AI Summary

Nexalin Technology announced the pricing of a $5.2 million public offering, involving 3,000,000 shares of common stock at $1.75 per share. The company expects to generate gross proceeds of approximately $5.25 million before fees and expenses. Maxim Group is the sole placement agent for this offering, which is scheduled to close on July 1, 2024, contingent on standard closing conditions. This offering was made under a registration statement declared effective by the SEC on June 27, 2024. The final prospectus will be filed with the SEC, and copies can be obtained from Maxim Group

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.91%
Tags
-
Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL; NXLIW) announced positive outcomes from a clinical study on their Deep Intracranial Frequency Stimulation (DIFS®) technology combined with escitalopram (Lexapro) for treating major depressive disorder (MDD). The 4-week, double-blind, randomized trial included 66 participants. Results showed that 66.7% of patients receiving the combination therapy improved, compared to 33.3% in the control group. The study revealed significant reductions in Hamilton Depression Rating Scale (HAMD-17) scores and found no serious adverse events. These findings were published in the journal Brain Stimulation, affirming the efficacy and feasibility of combining tACS with antidepressants for MDD treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.8%
Tags
Rhea-AI Summary

Nexalin Technology announced that the USPTO has awarded it U.S. Patent No 12,011,591 for its non-invasive Deep Intracranial Frequency Stimulation (DIFS®) device, designed to treat Alzheimer's and dementia-related diseases. The patent covers the Gen-2 and Gen-3 devices that use a proprietary frequency-based waveform for pain-free, undetectable brain stimulation. The global dementia treatment market is projected to grow from over $18 billion to $28 billion by 2030. The device also holds potential for other mental health disorders, including depression, migraines, anxiety, insomnia, addiction, and PTSD. The new patent enhances Nexalin's intellectual property portfolio and reflects significant advancements over the Gen-1 system. CEO Mark White emphasized the importance of this milestone, highlighting the growing need for innovative treatments in the expanding dementia market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
none
-
Rhea-AI Summary

RedChip Companies will air interviews with Nexalin Technology (Nasdaq:NXL) and VolitionRX (NYSE American:VNRX) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, June 15, at 7 p.m. ET. Nexalin's CEO, Mark White, discusses their non-invasive neurostimulation technology for mental health conditions like insomnia, PTSD, and traumatic brain injuries. Volition's CEO, Cameron Reynolds, highlights their epigenetic markers for diagnostics, focusing on cancer and sepsis. Volition aims for cash flow neutrality by 2025 through non-dilutive funding, revenue growth, and cost reduction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.86%
Tags
none
-
Rhea-AI Summary

Nexalin Technology announced the regulatory approval of its Gen-2, 15 mA neurostimulation device by the Brazilian Health Regulatory Agency (Anvisa) on June 13, 2024. This marks Nexalin's second regulatory approval outside China this year. Brazil, the ninth largest economy globally with over 215 million people, includes more than 35 million individuals suffering from mental health disorders. CEO Mark White highlighted the strategic importance of this approval, positioning it as a gateway to broader South American markets. Nexalin is in advanced talks with a key distributor in Brazil, promising more updates soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
125.05%
Tags
none
Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL; NXLIW) announced its participation in the Spring MicroCap Rodeo Conference on June 6, 2024, in New York City. CEO Mark White will present at 10:00 a.m. Eastern Time, with the presentation available via live webcast. Nexalin's management will also hold one-on-one meetings with approved investors throughout the event. Further details and registration for the conference can be found on the MicroCap Rodeo website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences
-
Rhea-AI Summary

Nexalin Technology announced that the FDA has provided feedback and reached consensus on the design for clinical studies of its Gen-3 HALO Clarity™ headset. These studies, focusing on anxiety and insomnia, are set to commence in Q3 2024. Each study will involve 75 patients receiving active treatment and 75 receiving sham treatment. The HALO device uses Deep Intracranial Frequency Stimulation (DIFS™) to potentially offer an effective alternative to pharmacological treatments. Following the studies, Nexalin plans to submit a De Novo request to the FDA, seeking a new marketing pathway for the device.

The production of over 500 units of the HALO headset has started to support these studies. Nexalin aims to manage the patient-physician relationship through a virtual clinic model, allowing at-home use with remote monitoring by a physician. CEO Mark White sees this as a significant step towards revolutionizing mental health treatment standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary

Nexalin Technology announced that its new division, Nexalin America, has joined the National Traumatic Brain Injury (TBI) Registry Coalition. This Coalition comprises private sector and non-profit organizations dedicated to advancing research, raising awareness, and supporting clinical trials for TBI, affecting millions annually. Members include the NFL Players Association, Spaulding Rehabilitation at Mass General, United States Brain Injury Alliance, Abbott, and American Academy of Neurology. Nexalin America will leverage its neurostimulation technology expertise to contribute to developing a national TBI registry. CEO Mark White highlighted this partnership as a significant step towards combating brain injuries through advanced technology and collaborative research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Nexalin Technology, Inc. is hosting an exclusive live investor webinar on May 23, 2024, featuring CEO Mark White discussing the company's clinical data on its deep brain stimulation device and new clinic model. Investors can register for the event and submit questions online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none

FAQ

What does Nexalin Technology, Inc. do?

Nexalin Technology, Inc. develops non-invasive, drug-free neurostimulation devices to treat anxiety, depression, and insomnia.

What is the core product of Nexalin Technology?

Nexalin's core product is the Gen-1 device, a cranial electrotherapy stimulation (CES) device that emits a unique waveform to normalize neurochemical levels.

Is the Nexalin device FDA approved?

Yes, Nexalin's Gen-1 device is classified as a Class II medical device by the FDA.

What recent achievements has Nexalin Technology made?

Nexalin recently announced a successful clinical study involving veteran patients with PCS and PTSD and obtained approval for its Gen-2 device in China.

How does Nexalin’s technology work?

Nexalin's technology uses transcranial electrical stimulation (tES) to stimulate brain activity and adjust neurochemical levels without drugs or psychotherapy.

What makes Nexalin's therapy unique?

Nexalin's therapy is non-invasive, drug-free, and designed to be undetectable to the human body, providing lasting relief without side effects.

Where is Nexalin's Gen-2 device approved for use?

The Gen-2 device has been approved by the National Medical Products Administration (NMPA) in China for treating insomnia and depression.

What ongoing projects is Nexalin Technology involved in?

Nexalin is currently gathering clinical data to support its technology and advancing its Gen-3 HALO™ Clarity Virtual Clinic model.

Who are Nexalin’s partners in distributing their devices?

Nexalin's devices are distributed in the Asia Pacific region through a joint venture with Wider Come Limited.

How can I get more information about Nexalin Technology's latest developments?

You can visit Nexalin's official website or contact Crescendo Communications, LLC for the latest updates.

Nexalin Technology, Inc.

Nasdaq:NXL

NXL Rankings

NXL Stock Data

15.03M
7.59M
22.98%
1.28%
12.88%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
HOUSTON